R Angelo de Claro

22PUBLICATIONS
145CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Aug 05, 2026
FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.

|Apr 30, 2026
Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States.

|Apr 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.

|Mar 06, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.

Sandra J Casak, Yiming Zhang, Chi Song

|Jan 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Yufan Liu, Jeannette Nashed, Amy K Barone

Pageof 4

Frequent Collaborators

12 joint publications

Marc Theoret

10 joint publications

Kelly Norsworthy

9 joint publications

Richard Pazdur

9 joint publications

Jonathon Vallejo